Cancer ResearchCancer BiologyPeer-reviewed journal article
Periostin+ stromal cells guide lymphovascular invasion by cancer cells
J. L. Null, D. J. Kim, J. V. McCann, P. Pramoonjago, J. W. Fox, P. Kumar, L. Edatt, C. V. Pecot, A. C. Dudley
Abstract
Cancer cell dissemination to the sentinel lymph node associates with poor patient outcomes, particularly in breast cancers. How cancer cells egress the primary tumor upon interfacing with the lymphatic vasculature is complex and driven by dynamic interactions between cancer cells and stromal cells including cancer associated fibroblasts (CAFs). The matricellular protein periostin can distinguish CAF subtypes in breast cancer and is associated with increased desmoplasia and disease recurrence in patients. However, since periostin is secreted, periostin-expressing CAFs are difficult to characterize in situ, limiting our understanding of their specific contribution to cancer progression. Here, we used in vivo genetic labelling and ablation to lineage trace periostin+ cells and characterize their function(s) during tumor growth and metastasis. We report that periostin-expressing CAFs are spatially found at periductal and perivascular margins, are enriched at lymphatic vessel peripheries, and are differentially activated by highly-metastatic cancer cells versus low-metastatic counterparts. Surprisingly, genetically depleting periostin+ CAFs slightly accelerated primary tumor growth but impaired intratumoral collagen organization and inhibited lymphatic, but not lung, metastases. Periostin ablation in CAFs impaired their ability to deposit aligned collagen matrices and inhibited cancer cell invasion through collagen and across lymphatic endothelial cell monolayers. Thus, highly-metastatic cancer cells mobilize periostin-expressing CAFs in the primary tumor site which promote collagen remodeling and collective cell invasion within lymphatic vessels and ultimately to sentinel lymph nodes. Significance StatementMetastatic disease causes the majority of cancer-related deaths but is challenging to treat as it is a complex multi-step process driven by heterotypic cell interactions. Cancer-associated fibroblasts (CAFs) are abundant in most solid tumors and display pro-tumorigenic and pro-metastatic functions, but extensive molecular diversity among CAFs has yielded contradictory results in previous attempts to target this population. Therefore, there is a need to identify markers of CAF subpopulations that promote or inhibit metastasis and functionally characterize them to understand their contributions during tumor progression. Our work identifies a population of CAFs, marked by expression of the matricellular protein periostin, that remodel the ECM to promote the escape of cancer cells into lymphatic vessels thereby driving colonization of proximal lymph nodes.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Pre-metastatic niche drives breast cancer invasion by modulating MSC homing and CAF differentiation
N. Saxena, G. Bhardwaj, … S. Sen·bioRxiv·Jan 12, 2021
- Breast cancer cell migration is potentiated by associated fibroblasts through a laminin-511-driven cortical localization of Arp2/3
Mallar Banerjee, Sudiksha Mishra, … Ramray Bhat·bioRxiv·Aug 10, 2025
- CD26-negative and CD26-positive tissue-resident fibroblasts contribute to functionally distinct CAF subpopulations in breast cancer
J. M. Houthuijzen, R. de Bruijn, … J. Jonkers·bioRxiv·Sep 27, 2022
- Cancer Associated Fibroblasts Mediate Cancer Progression and Remodel the Tumouroid Stroma
J. Pape, T. Magdeldin, … U. Cheema·bioRxiv·Nov 29, 2019
- Inter-Spheroid Proximity and Matrix Remodeling Determine CAF-Mediated Cancer Cell Invasion
Pranav Mehta, Ankur Bordoloi, … Pouyan Esmailzadeh Boukany·bioRxiv·Apr 24, 2025
- Myofibroblastic CAFs arising from bone-resident osteoblast precursors retain an osteolineage signature and support breast cancer progression via Osterix-mediated signaling.
Giulia Furesi, Carisa Zeng, … Roberta Faccio·bioRxiv·Sep 18, 2025